Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours

10 Feb 2025

Abstract excerpt

ER/PR+HER2- breast tumours are the most predominant subtype of breast cancer worldwide, including India. Unlike TNBCs, these tumours can be treated with anti-estrogens or aromatase inhibitors. Despite the success of endocrine therapy, a fraction of patients with ER/PR+ breast tumours do not respond to hormone-receptor-specific treatment and encounter disease recurrence contributing to their poor survival. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39930151
DOI: 10.1038/s42003-025-07606-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursPMID 39930151Read ↗

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity Read ↗

Endocrine therapy resistance: new insights.Semantic proximity Read ↗

Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity Read ↗

Complex rearrangements fuel ER+ and HER2+ breast tumoursSemantic proximity Read ↗

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancerSemantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerSemantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerSemantic proximity Read ↗

Clonal selection supported by single cell Dna sequencing reveals hormonal adaptation and resistance in locally advanced breast cancer During Neoadjuvant Aromatase InhibitionSemantic proximity Read ↗

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.